ACTT-1
2020
Remdesivir for the Treatment of COVID-19
In 1,062 hospitalised COVID-19 patients, remdesivir shortened time to recovery compared with placebo.
Result
Primary endpoint: Time to recovery
10 vs 15 days; 28-d mortality 11.4% vs 15.2% (HR 0.73; NS).
- Subtopic
- Antivirals
- Design
- Double-blind RCT, NIAID
- Relevance
- Supporting: context rather than must-know.
- Source
- Beigel JH, et al. N Engl J Med. 2020;383(19):1813-1826.doi 10.1056/NEJMoa2007764
Discussion & critique
Faster recovery without convincing mortality signal; later WHO SOLIDARITY pooling neutral.
Discussed in podcasts
- This Week in Cardiology · 4 episodes, latest 30 Oct 2020 (Listen)
- Core IM | Internal Medicine Podcast · #76 COVID Management Update · 30 Sept 2020 (Listen)
- Breakpoints · #25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More · 18 Jun 2020 (Listen)
- Freely Filtered, a NephJC Podcast · 2 episodes, latest 15 Jun 2020 (Listen)
- The Skeptics Guide to Emergency Medicine · SGEM Xtra: COVID19 Treatments – Be Skeptical · 9 May 2020 (Listen)On Trialsgram